Immunoglobulin G2 (IgG2-M)
Product Sizes
1 mg
16-16-090707-2M-1MG
5 mg
16-16-090707-2M-5MG
10 mg
16-16-090707-2M-10MG
About this Product
- SKU:
- 16-16-090707-2M
- Additional Names:
- Glycoproteomics, Inflammation, Biotherapeutics, In Vitro Diagnostic, Antimicrobial, Infection,|IgG2
- Buffer:
- Frozen in 20 mM phosphate, pH 7.4, with 150 mM NaCl and 0.05% NaN3.
- CE/IVD:
- RUO
- Extra Details:
- Serum IgG2 constitutes approximately 23% of total immunoglobulin G and is distinguished by a truncated 12-amino-acid hinge region with a poly-proline helix stabilized by four interchain disulfide bonds. This rigid structure limits Fab arm flexibility, reducing FcG Gamma receptor (FcG GammaR) binding and complement activation compared to IgG1/IgG3. However, IgG2 excels in targeting repetitive carbohydrate antigens on encapsulated bacteria like Streptococcus pneumoniae and Haemophilus influenzae, forming high-avidity interactions critical for polysaccharide immunity. Its Fc domain binds FcG GammaRIIA-H131 with moderate affinity, enabling phagocyte-mediated pathogen clearance in specific contexts. Deficiency in IgG2 (<2.1 g/L) impairs anti-polysaccharide responses, increasing susceptibility to recurrent sinopulmonary infections and invasive bacterial diseases. This deficiency often coexists with IgG4 or IgA deficits, complicating immune competence. Clinically, serum IgG2 quantification aids in evaluating humoral function, particularly in patients with chronic infections or hypogammaglobulinemia. Therapeutically, IgG2's reduced Fc-mediated effector functions are exploited in oncology. Panitumumab, an IgG2 anti-EGFR monoclonal antibody, minimizes cytokine release syndrome while retaining tumor-targeting efficacy. Its inefficient FcRn-mediated transcytosis-attributed to the absence of Gly236 in the hinge-also results in lower placental transfer (~50% maternal levels), reducing fetal exposure risks. Emerging engineering strategies leverage IgG2's structural stability for prolonged serum half-life and minimized off-target activation, enhancing therapeutic safety profiles.
- Formulation:
- Frozen in 20 mM phosphate, pH 7.4, with 150 mM NaCl and 0.05% NaN3.
- Molecular Weight:
- 146,000 Da
- Physical State:
- Frozen
- Purity:
- ≥95%
- Purification:
- Liquid Chromatography Methods
- Shipping Conditions:
- Dry Ice
- Source:
- Source human myeloma plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
- Storage Conditions:
- Please refer to datasheet
- Supplier:
- Athens Research & Technology Inc.
- Type:
- Antibody: Isotype Controls
